Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial.
about
Direct Delivery of Antigens to Dendritic Cells via Antibodies Specific for Endocytic Receptors as a Promising Strategy for Future TherapiesUpdate on the challenges and recent advances in cancer immunotherapyInsights into dendritic cell function using advanced imaging modalities.Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients.Personalized cell-mediated immunotherapy and vaccination: combating detrimental uprisings of malignanciesNovel anti-melanoma treatment: focus on immunotherapy.α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial.CD8+ TIL recruitment may revert the association of MAGE A3 with aggressive features in thyroid tumorsInactivation of DNA-dependent protein kinase promotes heat-induced apoptosis independently of heat-shock protein induction in human cancer cell lines.Antigen-loaded dendritic cell migration: MR imaging in a pancreatic carcinoma model.Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans.Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment.A novel therapy for melanoma developed in mice: transformation of melanoma into dendritic cells with Listeria monocytogenes.Lentivirus-induced 'Smart' dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanomaTissue-resident dendritic cells and diseases involving dendritic cell malfunctionExceptional antineoplastic activity of a dendritic-cell-targeted vaccine loaded with a Listeria peptide proposed against metastatic melanoma.Enhancing the treatment effect on melanoma by heat shock protein 70-peptide complexes purified from human melanoma cell lines.Immune-maximizing (IMAX) therapy for cancer: Combination of dendritic cell vaccine and intensity-modulated radiation.MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines.New clinical advances in immunotherapy for the treatment of solid tumours.Tumor Vaccines for Malignant Gliomas.Functional OCT4-specific CD4(+) and CD8(+) T cells in healthy controls and ovarian cancer patients.mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma.miR-128 enhances dendritic cell-mediated anti-tumor immunity via targeting of p38.Trial watch: Dendritic cell-based interventions for cancer therapy.Antitumor Vaccines Based on Dendritic Cells: From Experiments using Animal Tumor Models to Clinical Trials.Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.Dendritic cell therapy in melanoma.Development of effective tumor immunotherapy using a novel dendritic cell-targeting Toll-like receptor ligand.Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC.Cancer-testis antigens are predominantly expressed in uterine leiomyosarcoma compared with non-uterine leiomyosarcoma.Caveolin-1 Expression Increases upon Maturation in Dendritic Cells and Promotes Their Migration to Lymph Nodes Thereby Favoring the Induction of CD8+ T Cell Responses.Melanoma: a prototype of cancer-testis antigen-expressing malignancies.Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial)Mouse dendritic cell migration in abdominal lymph nodes by intraperitoneal administration
P2860
Q26752558-5958A1B5-B8A9-43B0-A373-99907E3FBCE1Q27014693-CC98AF63-6967-48D5-81E0-B5EFFBF1B6C0Q30532435-63A02379-BB1D-4D83-B603-B7863B055130Q30846001-32580F0F-DB07-4C16-AC35-E508E96E5DC7Q33361158-61770C32-6D31-4058-BEFB-5ABB4DA583DAQ34309404-7F63FFF3-1FF6-4D80-8620-08B9B7C3CA8CQ34523918-7C5EC4F4-0870-4FAF-8EA3-C5369D623A93Q34532807-A0546715-5C30-4650-8275-43BA77F29D14Q34625724-F84CF5D1-3941-4DA5-BD60-52733BE17DC5Q35038974-6E3D789F-FA81-4F4C-A094-4319E03BDBCDQ35044333-7966C05D-605E-45AB-9082-33B26C788596Q35063621-ECB57239-4787-4544-820D-8C6003A421EEQ35168418-9787D56C-C034-4500-BA1A-D28EEFAA5673Q36031874-30B412EA-6CCB-4828-87E0-853084AAEBCDQ36759434-441C1659-C5AC-4BCA-A1C4-240A77F112F1Q37086138-32657373-DABC-442E-A80D-DF3210DA8954Q37142487-4C099D92-B52A-4342-BDB4-7EF52FAA0DB3Q37560241-21B5700E-D261-4D69-99E4-ADCF551719E9Q37709626-96762804-F992-42D8-AB38-27233278E531Q38397279-7CEB6C4F-8235-4518-92D6-6DD6DC256FF6Q39228039-CE1476FA-5101-468E-879D-AA492BCC0E79Q41220323-34EE137B-2524-471E-A2C7-4BA9C56AE745Q41297982-D7D18351-2CCF-4CE4-A1EC-BD6295AB5CD8Q42835949-8B58B9C6-BC50-4437-B482-421C50207E02Q42867339-40EEF3EB-D581-4C97-A2EC-A5D493F8A30BQ42925679-1DC6986B-F4AB-4F38-912C-688E7EA8EE4CQ43147493-AFFB9E0D-26CF-467F-951C-67295D776BF7Q43923587-C6BF2293-9D72-4E8D-98A5-B3CD46AF3880Q47117087-86CAF78B-3084-4F6B-B482-F0810F459CCDQ47160856-BE940103-5845-4597-89B3-661C416F1B7BQ49335269-E7242DF4-3873-44CB-A556-84D2F32D2606Q49691061-708E682B-8DB1-4EC6-925D-FBFD95A509B7Q50070352-B0462315-68C1-4740-9B44-FC6884DABE25Q56523838-06D6B85F-4CE7-4197-9C3E-23AFB88A93DDQ57493380-7CE88CE4-CE18-4073-949A-85C0AA4E7D7C
P2860
Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Dendritic cell-based vaccinati ...... ents: phase II clinical trial.
@ast
Dendritic cell-based vaccinati ...... ents: phase II clinical trial.
@en
type
label
Dendritic cell-based vaccinati ...... ents: phase II clinical trial.
@ast
Dendritic cell-based vaccinati ...... ents: phase II clinical trial.
@en
prefLabel
Dendritic cell-based vaccinati ...... ents: phase II clinical trial.
@ast
Dendritic cell-based vaccinati ...... ents: phase II clinical trial.
@en
P2093
P2860
P356
P1433
P1476
Dendritic cell-based vaccinati ...... ents: phase II clinical trial.
@en
P2093
Akifumi Yamamoto
Akiko Kume
Akira Iizuka
Chie Oshita
Haruo Miyata
Kazutoh Takesako
Ken Yamaguchi
Masako Takikawa
Naoya Yamazaki
Ryuji Tanosaki
P2860
P304
P356
10.3892/OR.2012.1956
P577
2012-08-07T00:00:00Z